Free Trial

Anavex Life Sciences (AVXL) Financials

Anavex Life Sciences logo
$7.70 +0.12 (+1.60%)
As of 01:02 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.
Annual Income Statements for Anavex Life Sciences

Annual Income Statements for Anavex Life Sciences

This table shows Anavex Life Sciences' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2024 2023 2022
Period end date 9/30/2024 9/30/2023 9/30/2022
Net Income / (Loss) Attributable to Common Shareholders
-43 -48 -48
Consolidated Net Income / (Loss)
-43 -48 -48
Net Income / (Loss) Continuing Operations
-43 -48 -48
Total Pre-Tax Income
-43 -47 -48
Total Operating Income
-53 -56 -51
Total Gross Profit
0.00 0.00 0.00
Total Revenue
0.00 0.00 0.00
Total Cost of Revenue
0.00 0.00 0.00
Total Operating Expenses
53 56 51
Selling, General & Admin Expense
11 12 13
Research & Development Expense
42 44 38
Total Other Income / (Expense), net
9.88 8.26 3.37
Interest Expense
-7.32 -6.52 -0.95
Interest & Investment Income
2.29 2.72 3.32
Other Income / (Expense), net
0.26 -0.98 -0.90
Income Tax Expense
0.00 0.01 0.36
Basic Earnings per Share
($0.52) ($0.60) -
Weighted Average Basic Shares Outstanding
83.47M 79.79M -0.62
Diluted Earnings per Share
($0.52) ($0.60) -
Weighted Average Diluted Shares Outstanding
83.47M 79.79M -0.62
Weighted Average Basic & Diluted Shares Outstanding
84.82M 82.09M -0.62

Quarterly Income Statements for Anavex Life Sciences

This table shows Anavex Life Sciences' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022
Period end date 12/31/2024 9/30/2024 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023 12/31/2022 9/30/2022 6/30/2022
Net Income / (Loss) Attributable to Common Shareholders
-12 -12 -12 -11 -8.62 -10 -11 -13 -13 -14 -12
Consolidated Net Income / (Loss)
-12 -12 -12 -11 -8.62 -10 -11 -13 -13 -14 -12
Net Income / (Loss) Continuing Operations
-12 -12 -12 -11 -8.62 -10 -11 -13 -13 -14 -12
Total Pre-Tax Income
-12 -12 -12 -10 -8.62 -10 -11 -13 -13 -14 -12
Total Operating Income
-14 -14 -15 -13 -11 -13 -14 -14 -15 -15 -12
Total Gross Profit
0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Revenue
0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Cost of Revenue
0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Operating Expenses
14 14 15 13 11 13 14 14 15 15 12
Selling, General & Admin Expense
3.15 2.78 2.86 2.79 2.69 2.59 3.25 2.88 3.32 3.90 3.19
Research & Development Expense
10 12 12 9.73 8.68 10 10 11 12 11 9.27
Total Other Income / (Expense), net
1.48 2.59 2.45 2.08 2.76 2.44 2.29 1.13 2.39 1.20 0.18
Interest Expense
-1.39 -1.70 -1.86 -1.76 -2.01 -1.96 -1.83 -1.47 -1.27 -0.70 -0.23
Interest & Investment Income
0.41 0.70 0.53 0.47 0.59 0.67 0.57 0.75 0.73 0.99 0.68
Other Income / (Expense), net
-0.33 0.19 0.07 -0.15 0.16 -0.19 -0.10 -1.08 0.39 -0.50 -0.73
Basic Earnings per Share
($0.14) - ($0.14) ($0.13) ($0.11) - ($0.14) ($0.17) - - -
Weighted Average Basic Shares Outstanding
84.81M 83.47M 84.54M 82.46M 82.08M 79.79M 80.88M 78.30M 77.98M -0.62 -0.16
Diluted Earnings per Share
($0.14) - ($0.14) ($0.13) ($0.11) - ($0.14) ($0.17) - - -
Weighted Average Diluted Shares Outstanding
84.81M 83.47M 84.54M 82.46M 82.08M 79.79M 80.88M 78.30M 77.98M -0.62 -0.16
Weighted Average Basic & Diluted Shares Outstanding
85.06M 84.82M 84.80M 84.64M 82.11M 82.09M -0.14 78.30M 77.98M -0.62 77.44M

Annual Cash Flow Statements for Anavex Life Sciences

This table details how cash moves in and out of Anavex Life Sciences' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2024 2023 2022
Period end date 9/30/2024 9/30/2023 9/30/2022
Net Change in Cash & Equivalents
-19 1.87 -2.95
Net Cash From Operating Activities
-31 -28 -24
Net Cash From Continuing Operating Activities
-31 -28 -24
Net Income / (Loss) Continuing Operations
-43 -48 -48
Consolidated Net Income / (Loss)
-43 -48 -48
Non-Cash Adjustments To Reconcile Net Income
9.36 17 18
Changes in Operating Assets and Liabilities, net
2.83 2.51 5.36
Net Cash From Investing Activities
0.00 0.00 0.00
Net Cash From Continuing Investing Activities
0.00 0.00 0.00
Net Cash From Financing Activities
12 30 21
Net Cash From Continuing Financing Activities
12 30 21
Issuance of Common Equity
11 28 21
Other Financing Activities, net
0.69 1.78 1.01

Quarterly Cash Flow Statements for Anavex Life Sciences

This table details how cash moves in and out of Anavex Life Sciences' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022
Period end date 12/31/2024 9/30/2024 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023 12/31/2022 9/30/2022 6/30/2022
Net Change in Cash & Equivalents
-11 -6.57 -0.63 -4.38 -7.26 -3.79 1.35 9.85 -5.54 -4.04 -0.14
Net Cash From Operating Activities
-12 -6.66 -5.18 -12 -7.32 -5.85 -7.65 -8.49 -5.79 -4.04 -7.05
Net Cash From Continuing Operating Activities
-12 -6.66 -5.18 -12 -7.32 -5.85 -7.65 -8.49 -5.79 -4.04 -7.05
Net Income / (Loss) Continuing Operations
-12 -12 -12 -11 -8.62 -10 -11 -13 -13 -14 -12
Consolidated Net Income / (Loss)
-12 -12 -12 -11 -8.62 -10 -11 -13 -13 -14 -12
Non-Cash Adjustments To Reconcile Net Income
2.06 2.00 2.43 2.65 2.29 3.19 3.87 4.82 5.35 6.04 3.99
Changes in Operating Assets and Liabilities, net
-2.06 2.97 4.61 -3.76 -0.98 1.11 -0.24 -0.20 1.83 4.20 1.33
Net Cash From Investing Activities
0.00 - - - 0.00 - - - 0.00 - -
Net Cash From Continuing Investing Activities
0.00 - - - 0.00 - - - 0.00 - -
Net Cash From Financing Activities
0.71 0.09 4.55 7.28 0.06 2.06 9.00 18 0.26 0.00 6.91
Net Cash From Continuing Financing Activities
0.71 0.09 4.55 7.28 0.06 2.06 9.00 18 0.26 0.00 6.91
Other Financing Activities, net
0.71 0.09 0.44 0.10 0.06 0.87 0.47 0.18 0.26 -0.00 0.51

Annual Balance Sheets for Anavex Life Sciences

This table presents Anavex Life Sciences' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2024 2023 2022
Period end date 9/30/2024 9/30/2023 9/30/2022
Total Assets
136 154 153
Total Current Assets
133 152 153
Cash & Equivalents
132 151 149
Prepaid Expenses
0.93 0.65 0.35
Plant, Property, & Equipment, net
0.00 0.00 0.00
Total Noncurrent Assets
2.45 2.71 0.00
Noncurrent Note & Lease Receivables
2.45 2.71 -
Total Liabilities & Shareholders' Equity
136 154 153
Total Liabilities
15 13 10
Total Current Liabilities
14 12 9.77
Accounts Payable
9.63 4.32 3.83
Accrued Expenses
4.84 7.30 5.95
Total Noncurrent Liabilities
0.84 0.92 0.44
Other Noncurrent Operating Liabilities
0.84 - 0.44
Commitments & Contingencies
0.00 0.00 0.00
Total Equity & Noncontrolling Interests
120 142 142
Total Preferred & Common Equity
120 142 142
Preferred Stock
0.00 0.00 0.00
Total Common Equity
120 142 142
Common Stock
456 435 388
Retained Earnings
-336 -293 -246

Quarterly Balance Sheets for Anavex Life Sciences

This table presents Anavex Life Sciences' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q1 2025 Q3 2024 Q2 2024 Q1 2024 Q3 2023 Q2 2023 Q1 2023 Q3 2022
Period end date 12/31/2024 6/30/2024 3/31/2024 12/31/2023 6/30/2023 3/31/2023 12/31/2022 6/30/2022
Total Assets
124 142 145 148 158 159 148 160
Total Current Assets
121 142 141 145 156 159 148 160
Cash & Equivalents
121 139 139 144 155 153 144 153
Prepaid Expenses
0.71 1.06 1.35 0.76 0.83 0.98 0.66 0.46
Plant, Property, & Equipment, net
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Noncurrent Assets
2.56 0.00 3.79 3.55 2.17 0.00 0.00 0.00
Noncurrent Note & Lease Receivables
2.56 - 3.79 3.55 2.17 - - -
Total Liabilities & Shareholders' Equity
124 142 145 148 158 159 148 160
Total Liabilities
13 12 9.56 12 11 14 13 9.48
Total Current Liabilities
12 11 8.64 12 10 13 12 9.48
Accounts Payable
4.57 3.50 3.73 4.29 4.15 6.28 5.29 3.13
Accrued Expenses
7.73 7.33 4.92 7.29 5.99 6.82 7.04 5.91
Total Noncurrent Liabilities
0.83 0.92 0.92 0.92 0.92 0.92 0.92 0.00
Other Noncurrent Operating Liabilities
0.83 0.92 0.92 0.92 0.92 0.92 0.92 -
Commitments & Contingencies
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests
111 130 135 136 147 145 135 151
Total Preferred & Common Equity
111 130 135 136 147 145 135 151
Preferred Stock
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity
111 130 135 136 147 145 135 151
Common Stock
459 454 447 437 430 417 394 382
Retained Earnings
-348 -324 -312 -302 -283 -272 -259 -231

Annual Metrics And Ratios for Anavex Life Sciences

This table displays calculated financial ratios and metrics derived from Anavex Life Sciences' official financial filings.

Metric 2024 2023 2022
Period end date 9/30/2024 9/30/2023 9/30/2022
Growth Metrics
- - -
Revenue Growth
0.00% 0.00% 0.00%
EBITDA Growth
7.27% -9.34% -22.92%
EBIT Growth
7.27% -9.34% -22.92%
NOPAT Growth
5.16% -9.36% -21.39%
Net Income Growth
9.48% 0.99% -26.56%
EPS Growth
13.33% 0.00% 0.00%
Operating Cash Flow Growth
-10.89% -14.63% 20.23%
Free Cash Flow Firm Growth
6.19% -20.49% -0.63%
Invested Capital Growth
-30.00% -37.57% -416.97%
Revenue Q/Q Growth
0.00% 0.00% 0.00%
EBITDA Q/Q Growth
-2.55% 4.93% -6.67%
EBIT Q/Q Growth
-2.55% 4.93% -6.67%
NOPAT Q/Q Growth
-3.29% 4.51% -6.32%
Net Income Q/Q Growth
-3.55% 8.02% -5.66%
EPS Q/Q Growth
0.00% 0.00% 0.00%
Operating Cash Flow Q/Q Growth
-2.70% -6.95% 13.03%
Free Cash Flow Firm Q/Q Growth
1.89% -3.55% 3.83%
Invested Capital Q/Q Growth
-32.86% -13.76% -170.71%
Profitability Metrics
- - -
Gross Margin
0.00% 0.00% 0.00%
EBITDA Margin
0.00% 0.00% 0.00%
Operating Margin
0.00% 0.00% 0.00%
EBIT Margin
0.00% 0.00% 0.00%
Profit (Net Income) Margin
0.00% 0.00% 0.00%
Tax Burden Percent
100.00% 100.01% 100.75%
Interest Burden Percent
81.73% 83.72% 91.77%
Effective Tax Rate
0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)
0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)
0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)
0.00% 0.00% 0.00%
Return on Equity (ROE)
-32.81% -33.41% -32.72%
Cash Return on Invested Capital (CROIC)
0.00% 0.00% 0.00%
Operating Return on Assets (OROA)
0.00% 0.00% 0.00%
Return on Assets (ROA)
0.00% 0.00% 0.00%
Return on Common Equity (ROCE)
-32.81% -33.41% -32.72%
Return on Equity Simple (ROE_SIMPLE)
-35.76% -33.49% -33.67%
Net Operating Profit after Tax (NOPAT)
-37 -39 -36
NOPAT Margin
0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)
-4.23% -5.65% -8.16%
Return On Investment Capital (ROIC_SIMPLE)
-30.78% -27.51% -
Cost of Revenue to Revenue
0.00% 0.00% 0.00%
SG&A Expenses to Revenue
0.00% 0.00% 0.00%
R&D to Revenue
0.00% 0.00% 0.00%
Operating Expenses to Revenue
0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)
-53 -57 -52
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
-53 -57 -52
Valuation Ratios
- - -
Price to Book Value (P/BV)
4.00 3.78 5.65
Price to Tangible Book Value (P/TBV)
4.00 3.78 5.65
Price to Revenue (P/Rev)
0.00 0.00 0.00
Price to Earnings (P/E)
0.00 0.00 0.00
Dividend Yield
0.00% 0.00% 0.00%
Earnings Yield
0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)
0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)
0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)
0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)
0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)
0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)
0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)
0.00 0.00 0.00
Leverage & Solvency
- - -
Debt to Equity
0.00 0.00 0.00
Long-Term Debt to Equity
0.00 0.00 0.00
Financial Leverage
-1.08 -1.06 -1.03
Leverage Ratio
1.11 1.08 1.07
Compound Leverage Factor
0.90 0.90 0.98
Debt to Total Capital
0.00% 0.00% 0.00%
Short-Term Debt to Total Capital
0.00% 0.00% 0.00%
Long-Term Debt to Total Capital
0.00% 0.00% 0.00%
Preferred Equity to Total Capital
0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital
0.00% 0.00% 0.00%
Common Equity to Total Capital
100.00% 100.00% 100.00%
Debt to EBITDA
0.00 0.00 0.00
Net Debt to EBITDA
0.00 0.00 0.00
Long-Term Debt to EBITDA
0.00 0.00 0.00
Debt to NOPAT
0.00 0.00 0.00
Net Debt to NOPAT
0.00 0.00 0.00
Long-Term Debt to NOPAT
0.00 0.00 0.00
Altman Z-Score
15.18 22.91 45.00
Noncontrolling Interest Sharing Ratio
0.00% 0.00% 0.00%
Liquidity Ratios
- - -
Current Ratio
9.20 13.06 15.63
Quick Ratio
9.14 13.00 15.27
Cash Flow Metrics
- - -
Free Cash Flow to Firm (FCFF)
-34 -37 -30
Operating Cash Flow to CapEx
0.00% 0.00% 0.00%
Free Cash Flow to Firm to Interest Expense
0.00 0.00 0.00
Operating Cash Flow to Interest Expense
0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense
0.00 0.00 0.00
Efficiency Ratios
- - -
Asset Turnover
0.00 0.00 0.00
Accounts Receivable Turnover
0.00 0.00 0.00
Inventory Turnover
0.00 0.00 0.00
Fixed Asset Turnover
0.00 0.00 0.00
Accounts Payable Turnover
0.00 0.00 0.00
Days Sales Outstanding (DSO)
0.00 0.00 0.00
Days Inventory Outstanding (DIO)
0.00 0.00 0.00
Days Payable Outstanding (DPO)
0.00 0.00 0.00
Cash Conversion Cycle (CCC)
0.00 0.00 0.00
Capital & Investment Metrics
- - -
Invested Capital
-12 -9.17 -6.67
Invested Capital Turnover
0.00 0.00 0.00
Increase / (Decrease) in Invested Capital
-2.75 -2.51 -5.38
Enterprise Value (EV)
349 386 655
Market Capitalization
482 537 804
Book Value per Share
$1.42 $1.73 $1.83
Tangible Book Value per Share
$1.42 $1.73 $1.83
Total Capital
120 142 142
Total Debt
0.00 0.00 0.00
Total Long-Term Debt
0.00 0.00 0.00
Net Debt
-132 -151 -149
Capital Expenditures (CapEx)
0.00 0.00 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)
-14 -11 -6.22
Debt-free Net Working Capital (DFNWC)
119 140 143
Net Working Capital (NWC)
119 140 143
Net Nonoperating Expense (NNE)
5.99 8.48 12
Net Nonoperating Obligations (NNO)
-132 -151 -149
Total Depreciation and Amortization (D&A)
0.00 0.00 0.00
Debt-free, Cash-free Net Working Capital to Revenue
0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue
0.00% 0.00% 0.00%
Net Working Capital to Revenue
0.00% 0.00% 0.00%
Earnings Adjustments
- - -
Adjusted Basic Earnings per Share
($0.52) $0.00 $0.00
Adjusted Weighted Average Basic Shares Outstanding
83.47M 82.09M 77.96M
Adjusted Diluted Earnings per Share
($0.52) $0.00 $0.00
Adjusted Weighted Average Diluted Shares Outstanding
83.47M 82.09M 77.96M
Adjusted Basic & Diluted Earnings per Share
$0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
84.82M 82.09M 76.91M
Normalized Net Operating Profit after Tax (NOPAT)
-37 -39 -36
Normalized NOPAT Margin
0.00% 0.00% 0.00%
Pre Tax Income Margin
0.00% 0.00% 0.00%
Debt Service Ratios
- - -
EBIT to Interest Expense
0.00 0.00 0.00
NOPAT to Interest Expense
0.00 0.00 0.00
EBIT Less CapEx to Interest Expense
0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense
0.00 0.00 0.00
Payout Ratios
- - -
Dividend Payout Ratio
0.00% 0.00% 0.00%
Augmented Payout Ratio
0.00% 0.00% -1.47%

Quarterly Metrics And Ratios for Anavex Life Sciences

This table displays calculated financial ratios and metrics derived from Anavex Life Sciences' official financial filings.

Metric Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022
Period end date 12/31/2024 9/30/2024 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023 12/31/2022 9/30/2022 6/30/2022
Growth Metrics
- - - - - - - - - - -
Revenue Growth
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth
-24.02% -10.18% -7.56% 17.04% 25.15% 18.64% -3.34% -35.74% -28.50% -25.88% -14.54%
EBIT Growth
-24.02% -10.18% -7.56% 17.04% 25.15% 18.64% -3.34% -35.74% -28.50% -25.88% -14.54%
NOPAT Growth
-19.46% -13.32% -8.85% 11.78% 26.04% 17.23% -8.61% -23.18% -31.22% -24.74% -9.30%
Net Income Growth
-40.47% -14.53% -8.28% 19.54% 33.53% 29.00% 8.79% -25.57% -19.20% -21.95% -21.49%
EPS Growth
-27.27% 0.00% 0.00% 23.53% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Cash Flow Growth
-65.62% -13.83% 32.31% -37.31% -26.30% -44.63% -8.50% 11.94% -65.50% 47.31% 6.22%
Free Cash Flow Firm Growth
5.17% -14.68% -142.72% -356.45% -17.34% -19.34% 41.97% 60.31% -57.20% 42.78% 36.47%
Invested Capital Growth
-20.39% -30.00% -11.32% 46.66% 3.62% -37.57% -227.38% -629.83% -77.83% -416.97% -494.41%
Revenue Q/Q Growth
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth
1.61% 3.53% -15.73% -13.76% 12.59% 5.82% 10.74% -1.86% 4.98% -19.62% -17.24%
EBIT Q/Q Growth
1.61% 3.53% -15.73% -13.76% 12.59% 5.82% 10.74% -1.86% 4.98% -19.62% -17.24%
NOPAT Q/Q Growth
5.19% 2.67% -17.65% -10.86% 10.06% 6.50% 4.64% 7.76% -0.65% -22.68% -8.15%
Net Income Q/Q Growth
-4.23% 4.86% -15.82% -22.32% 15.02% 10.05% 13.94% -1.04% 9.23% -15.55% -18.49%
EPS Q/Q Growth
0.00% 0.00% -7.69% 0.00% 0.00% 0.00% 17.65% 0.00% 0.00% 0.00% 0.00%
Operating Cash Flow Q/Q Growth
-82.04% -28.53% 55.56% -59.28% -25.12% 23.57% 9.85% -46.51% -43.27% 42.67% 26.83%
Free Cash Flow Firm Q/Q Growth
-7.71% 22.50% 25.63% -53.87% -30.26% -64.02% -39.85% 60.73% -32.47% 20.25% 4.34%
Invested Capital Q/Q Growth
17.31% -32.86% -102.69% 45.93% 10.71% -13.76% 2.88% 2.30% -27.46% -170.71% -116.50%
Profitability Metrics
- - - - - - - - - - -
Gross Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent
100.00% 98.95% 99.45% 101.01% 100.00% 99.37% 100.36% 100.38% 99.85% 101.49% 100.72%
Interest Burden Percent
87.02% 83.02% 83.76% 82.41% 76.83% 79.53% 82.45% 85.50% 86.65% 89.23% 93.08%
Effective Tax Rate
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)
-37.72% -32.81% -30.03% -28.98% -31.88% -33.41% -34.72% -35.47% -35.57% -32.72% -29.50%
Cash Return on Invested Capital (CROIC)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)
-37.72% -32.81% -30.03% -28.98% -31.88% -33.41% -34.72% -35.47% -35.57% -32.72% -29.50%
Return on Equity Simple (ROE_SIMPLE)
-41.92% 0.00% -32.00% -30.08% -31.83% 0.00% -35.19% -36.33% -37.05% 0.00% -30.12%
Net Operating Profit after Tax (NOPAT)
-9.51 -10 -10 -8.76 -7.96 -8.86 -9.47 -9.93 -11 -11 -8.72
NOPAT Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)
-1.96% -1.12% -1.30% -1.22% -0.46% -0.86% -1.17% -2.07% -1.49% -2.38% -2.35%
Return On Investment Capital (ROIC_SIMPLE)
-8.58% -8.34% - - -5.87% -6.24% - - - - -
Cost of Revenue to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)
-14 -14 -15 -13 -11 -13 -14 -15 -15 -16 -13
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
-14 -14 -15 -13 -11 -13 -14 -15 -15 -16 -13
Valuation Ratios
- - - - - - - - - - -
Price to Book Value (P/BV)
8.21 4.00 2.75 3.10 5.63 3.78 4.48 4.61 5.34 5.65 5.14
Price to Tangible Book Value (P/TBV)
8.21 4.00 2.75 3.10 5.63 3.78 4.48 4.61 5.34 5.65 5.14
Price to Revenue (P/Rev)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Earnings (P/E)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency
- - - - - - - - - - -
Debt to Equity
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage
-1.07 -1.08 -1.06 -1.05 -1.06 -1.06 -1.04 -1.03 -1.05 -1.03 -1.01
Leverage Ratio
1.10 1.11 1.08 1.08 1.10 1.08 1.07 1.07 1.08 1.07 1.06
Compound Leverage Factor
0.96 0.92 0.91 0.89 0.84 0.86 0.88 0.92 0.94 0.96 0.99
Debt to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital
100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score
38.39 16.12 15.79 24.02 34.61 23.85 33.98 27.01 31.02 45.78 47.85
Noncontrolling Interest Sharing Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios
- - - - - - - - - - -
Current Ratio
9.88 9.20 13.06 16.29 12.48 13.06 15.35 12.15 12.03 15.63 16.89
Quick Ratio
9.82 9.14 12.80 16.13 12.42 13.00 15.27 11.71 11.65 15.27 16.15
Cash Flow Metrics
- - - - - - - - - - -
Free Cash Flow to Firm (FCFF)
-7.84 -7.28 -9.40 -13 -8.27 -6.35 -3.87 -2.77 -7.05 -5.32 -6.67
Operating Cash Flow to CapEx
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Free Cash Flow to Firm to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios
- - - - - - - - - - -
Asset Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics
- - - - - - - - - - -
Invested Capital
-9.86 -12 -8.98 -4.43 -8.19 -9.17 -8.06 -8.30 -8.50 -6.67 -2.46
Invested Capital Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital
-1.67 -2.75 -0.91 3.87 0.31 -2.51 -5.60 -7.16 -3.72 -5.38 -2.05
Enterprise Value (EV)
790 349 218 279 619 386 502 515 578 655 622
Market Capitalization
911 482 357 418 763 537 657 669 722 804 775
Book Value per Share
$1.31 $1.42 $1.53 $1.64 $1.65 $1.73 $1.82 $1.86 $1.73 $1.83 $1.95
Tangible Book Value per Share
$1.31 $1.42 $1.53 $1.64 $1.65 $1.73 $1.82 $1.86 $1.73 $1.83 $1.95
Total Capital
111 120 130 135 136 142 147 145 135 142 151
Total Debt
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt
-121 -132 -139 -139 -144 -151 -155 -153 -144 -149 -153
Capital Expenditures (CapEx)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)
-12 -14 -8.06 -7.30 -11 -11 -9.31 -7.39 -7.58 -6.22 -2.46
Debt-free Net Working Capital (DFNWC)
109 119 131 132 133 140 146 146 136 143 151
Net Working Capital (NWC)
109 119 131 132 133 140 146 146 136 143 151
Net Nonoperating Expense (NNE)
2.60 1.58 1.90 1.78 0.66 1.29 1.81 3.17 2.20 3.59 3.65
Net Nonoperating Obligations (NNO)
-121 -132 -139 -139 -144 -151 -155 -153 -144 -149 -153
Total Depreciation and Amortization (D&A)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt-free, Cash-free Net Working Capital to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Working Capital to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Adjustments
- - - - - - - - - - -
Adjusted Basic Earnings per Share
($0.14) $0.00 ($0.14) ($0.13) $0.00 $0.00 $0.00 ($0.17) ($0.17) $0.00 ($0.16)
Adjusted Weighted Average Basic Shares Outstanding
84.81M 83.47M 84.54M 82.46M 82.11M 79.79M 81.95M 80.84M 78.03M -1.00 77.94M
Adjusted Diluted Earnings per Share
($0.14) $0.00 ($0.14) ($0.13) $0.00 $0.00 $0.00 ($0.17) ($0.17) $0.00 ($0.16)
Adjusted Weighted Average Diluted Shares Outstanding
84.81M 83.47M 84.54M 82.46M 82.11M 79.79M 81.95M 80.84M 78.03M -1.00 77.94M
Adjusted Basic & Diluted Earnings per Share
$0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 ($0.17) ($0.17) $0.00 ($0.16)
Adjusted Weighted Average Basic & Diluted Shares Outstanding
85.06M 84.82M 84.80M 84.64M 82.11M 82.09M 80.88M 78.30M 77.98M -1.00 77.44M
Normalized Net Operating Profit after Tax (NOPAT)
-9.51 -10 -10 -8.76 -7.96 -8.86 -9.47 -9.93 -11 -11 -8.72
Normalized NOPAT Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios
- - - - - - - - - - -
EBIT to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios
- - - - - - - - - - -
Dividend Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -1.47% 0.00%

Frequently Asked Questions About Anavex Life Sciences' Financials

When does Anavex Life Sciences's fiscal year end?

According to the most recent income statement we have on file, Anavex Life Sciences' financial year ends in September. Their financial year 2024 ended on September 30, 2024.

How has Anavex Life Sciences' net income changed over the last 2 years?

Anavex Life Sciences' net income appears to be on a downward trend, with a most recent value of -$43.00 million in 2024, falling from -$47.98 million in 2022. The previous period was -$47.51 million in 2023. See Anavex Life Sciences' forecast for analyst expectations on what’s next for the company.

What is Anavex Life Sciences's operating income?
Anavex Life Sciences's total operating income in 2024 was -$52.88 million, based on the following breakdown:
  • Total Gross Profit: $0.00
  • Total Operating Expenses: $52.88 million
How has Anavex Life Sciences revenue changed over the last 2 years?

Over the last 2 years, Anavex Life Sciences' total revenue changed from $0.00 in 2022 to $0.00 in 2024, a change of 0.0%.

How much debt does Anavex Life Sciences have?

Anavex Life Sciences' total liabilities were at $15.30 million at the end of 2024, a 22.1% increase from 2023, and a 49.8% increase since 2022.

How much cash does Anavex Life Sciences have?

In the past 2 years, Anavex Life Sciences' cash and equivalents has ranged from $132.19 million in 2024 to $151.02 million in 2023, and is currently $132.19 million as of their latest financial filing in 2024.

How has Anavex Life Sciences' book value per share changed over the last 2 years?

Over the last 2 years, Anavex Life Sciences' book value per share changed from 1.83 in 2022 to 1.42 in 2024, a change of -22.4%.



This page (NASDAQ:AVXL) was last updated on 5/29/2025 by MarketBeat.com Staff
From Our Partners